PE20241620A1 - Anticuerpos terapeuticos que se unen al dominio serina proteasa de masp-2 y usos de estos - Google Patents
Anticuerpos terapeuticos que se unen al dominio serina proteasa de masp-2 y usos de estosInfo
- Publication number
- PE20241620A1 PE20241620A1 PE2024001336A PE2024001336A PE20241620A1 PE 20241620 A1 PE20241620 A1 PE 20241620A1 PE 2024001336 A PE2024001336 A PE 2024001336A PE 2024001336 A PE2024001336 A PE 2024001336A PE 20241620 A1 PE20241620 A1 PE 20241620A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cdr2
- cdr3
- chain variable
- binding fragment
- Prior art date
Links
- 102000012479 Serine Proteases Human genes 0.000 title abstract 2
- 108010022999 Serine Proteases Proteins 0.000 title abstract 2
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 title 1
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000004856 Lectins Human genes 0.000 abstract 2
- 108090001090 Lectins Proteins 0.000 abstract 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000002523 lectin Substances 0.000 abstract 2
- 230000037361 pathway Effects 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 102000054960 human MASP2 Human genes 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a un anticuerpo aislado o fragmento de union a antigeno de este que se une especificamente a un epitopo situado dentro del dominio de la serina proteasa de la MASP-2 humana, caracterizado porque el anticuerpo o fragmento de union a antigeno de este, comprende: (a) una region variable de cadena pesada que comprende una HC-CDR1 que tiene secuencia NXXMH, HC-CDR2 establecida como la SEQ ID NO:63 (DIDXSDSEXYXXKFKD); y una HC-CDR3 establecida como SEQ ID NO:18 (GDITTTLRYFDV); y una region variable de cadena ligera que comprende una LC-CDR1 establecida como SEQ ID NO:64 (SASSSVXYMY); LC-CDR2 como SEQ ID NO:34 (DTSNLAS) y LC-CDR3 como SEQ ID NO:36 (QQWSSYPLT); o (b) una region variable de cadena pesada que comprende una HC-CDR1 establecida como SEQ ID NO:25 (SYWMH), HC-CDR2 como SEQ ID NO:27 (NINPSNGGTNCNEKFKN) y HC-CDR3 como SEQ ID NO:29 (WAYDAMDY) y LC-CDR1 como SEQ ID NO:41 (RASESVDSYGNSFMH), LC-CDR2 como SEQ ID NO:43 (FASNLES) y LC-CDR3 como SEQ ID NO: 45 (QQSNEDPLT). Estos anticuerpos inhiben la activacion del complemento de la via de la lectina. Tambien se refiere a una composicion que comprende dicho anticuerpo aislado o fragmento de union, un polinucleotido aislado que codifica sus regiones variables de cadena pesada y ligera, una combinacion de dicho polinucleotido, vectores de clonacion o de expresion, una celula hospedadora, proceso para producir dicho anticuerpo o fragmento de union a antigeno; y su uso para tratar una enfermedad o un trastorno relacionado con la via de la lectina o que esta en riesgo de padecerlo, tales como microangiopatia trombotica (TMA), afeccion renal, lesion isquemica por reperfusion, entre otros.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288174P | 2021-12-10 | 2021-12-10 | |
| US202263350580P | 2022-06-09 | 2022-06-09 | |
| PCT/US2022/081121 WO2023108028A2 (en) | 2021-12-10 | 2022-12-07 | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241620A1 true PE20241620A1 (es) | 2024-08-07 |
Family
ID=86731404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001336A PE20241620A1 (es) | 2021-12-10 | 2022-12-07 | Anticuerpos terapeuticos que se unen al dominio serina proteasa de masp-2 y usos de estos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230265215A1 (es) |
| EP (1) | EP4444758A2 (es) |
| KR (1) | KR20240116540A (es) |
| AU (1) | AU2022405100A1 (es) |
| CA (1) | CA3240483A1 (es) |
| CL (1) | CL2024001677A1 (es) |
| CO (1) | CO2024007207A2 (es) |
| CR (1) | CR20240271A (es) |
| IL (1) | IL313331A (es) |
| MX (1) | MX2024007065A (es) |
| PE (1) | PE20241620A1 (es) |
| TW (1) | TW202334242A (es) |
| WO (1) | WO2023108028A2 (es) |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| US7297348B2 (en) | 2002-07-19 | 2007-11-20 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20140056873A1 (en) | 2004-06-10 | 2014-02-27 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| KR101788040B1 (ko) * | 2009-10-16 | 2017-10-19 | 오메로스 코포레이션 | Ｍａｓｐ－2 의존성 보체 활성화의 억제에 의한 파종성 혈관내 응고의 치료 방법 |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP2694108B1 (en) | 2011-04-08 | 2018-06-06 | University Of Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| RU2636038C2 (ru) | 2011-05-04 | 2017-11-17 | Омерос Корпорейшн | Композиции для ингибирования masp-2-зависимой активации комплемента |
| EP2581388A1 (en) * | 2011-10-14 | 2013-04-17 | Centre National de la Recherche Scientifique (CNRS) | Anti-sPLA2-V antibodies and uses thereof |
| EP3878865A3 (en) | 2012-06-18 | 2021-12-08 | Omeros Corporation | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| EP3057993B1 (en) | 2013-10-17 | 2020-08-12 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| US10519251B2 (en) | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| EP3373963A4 (en) | 2015-11-09 | 2019-07-10 | Omeros Corporation | METHODS OF TREATING SUFFERING RELATED TO MASP-2-DEPENDENT COMPLEMENTAL ACTIVATION |
| US20170253667A1 (en) | 2016-01-05 | 2017-09-07 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| UA127339C2 (uk) | 2016-01-05 | 2023-07-26 | Юніверсіті Оф Лестер | СПОСІБ ПРОФІЛАКТИКИ АБО ЗМЕНШЕННЯ УРАЖЕННЯ НИРОК У СУБ'ЄКТА, ЩО СТРАЖДАЄ НА СТЕРОЇДЗАЛЕЖНУ ІМУНОГЛОБУЛІН-А-НЕФРОПАТІЮ (IgAN) |
| IL262021B2 (en) | 2016-03-31 | 2024-01-01 | Omeros Corp | MASP-2 inhibitory agents for use in suppressing angiogenesis |
| EP3448987A4 (en) * | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| US20180105604A1 (en) | 2016-10-13 | 2018-04-19 | University Of Leicester | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
| JOP20190068A1 (ar) | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
| TWI818919B (zh) | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法 |
| MA50188A (fr) | 2017-09-22 | 2021-06-02 | Wuxi Biologics Ireland Ltd | Nouveaux complexes polypeptidiques bispécifiques |
| KR20220104201A (ko) | 2019-11-26 | 2022-07-26 | 오메로스 코포레이션 | 조혈 줄기 세포 이식과 관련된 특발성 폐렴 증후군 (ips) 및/또는 모세혈관 누출 증후군 (cls) 및/또는 생착 증후군 (es) 및/또는 체액 과부하 (fo)를 치료 및/또는 예방하는 방법 |
| TWI834025B (zh) | 2020-03-06 | 2024-03-01 | 美商奥默羅斯公司 | 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法 |
-
2022
- 2022-12-07 TW TW111146896A patent/TW202334242A/zh unknown
- 2022-12-07 US US18/063,018 patent/US20230265215A1/en active Pending
- 2022-12-07 MX MX2024007065A patent/MX2024007065A/es unknown
- 2022-12-07 IL IL313331A patent/IL313331A/en unknown
- 2022-12-07 KR KR1020247022585A patent/KR20240116540A/ko active Search and Examination
- 2022-12-07 CA CA3240483A patent/CA3240483A1/en active Pending
- 2022-12-07 AU AU2022405100A patent/AU2022405100A1/en active Pending
- 2022-12-07 WO PCT/US2022/081121 patent/WO2023108028A2/en active Application Filing
- 2022-12-07 EP EP22905349.1A patent/EP4444758A2/en active Pending
- 2022-12-07 CR CR20240271A patent/CR20240271A/es unknown
- 2022-12-07 PE PE2024001336A patent/PE20241620A1/es unknown
-
2023
- 2023-08-15 US US18/450,194 patent/US12091468B2/en active Active
-
2024
- 2024-06-06 CL CL2024001677A patent/CL2024001677A1/es unknown
- 2024-06-07 CO CONC2024/0007207A patent/CO2024007207A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4444758A2 (en) | 2024-10-16 |
| KR20240116540A (ko) | 2024-07-29 |
| CL2024001677A1 (es) | 2024-09-13 |
| TW202334242A (zh) | 2023-09-01 |
| CO2024007207A2 (es) | 2024-07-18 |
| WO2023108028A2 (en) | 2023-06-15 |
| AU2022405100A1 (en) | 2024-07-25 |
| CR20240271A (es) | 2024-08-12 |
| US20240101709A1 (en) | 2024-03-28 |
| IL313331A (en) | 2024-08-01 |
| US12091468B2 (en) | 2024-09-17 |
| US20230265215A1 (en) | 2023-08-24 |
| CA3240483A1 (en) | 2023-06-15 |
| MX2024007065A (es) | 2024-06-20 |
| WO2023108028A3 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| PE20180249A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
| EA202092933A1 (ru) | Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии | |
| PE20181310A1 (es) | Anticuerpos anti-il1rap, moleculas de union a antigenos biespecificas que se unen a il1rap y cd3, y usos de estos | |
| PE20191661A1 (es) | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos | |
| PE20190389A1 (es) | Composiciones y metodos de inhibicion del masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| PE20211284A1 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| PE20170767A1 (es) | Diacuerpos enlazados covalentemente que tienen inmunoreactividad con pd-1 y lag-3, y metodos de uso de los mismos | |
| PE20231078A1 (es) | Anticuerpos anti-tigit | |
| AR041650A1 (es) | Anticuerpos que se unen a polipeptidos ca125/o772p cuando estos se encuentran asociados a las celulas. metodos relacionados | |
| PE20120832A1 (es) | Proteinas de union al antigeno del receptor a de la il-17 | |
| CO6180451A2 (es) | Polipeptidos heterodimericos il -17 a/f y usos terapeuticos de los mismos | |
| EA202092302A1 (ru) | Антитела к trem-1 и их применения | |
| PE20230385A1 (es) | Anticuerpos anti-phf-tau y usos de estos | |
| PE20191319A1 (es) | Anticuerpos novedosos contra el factor xi y sus usos | |
| PE20201149A1 (es) | Anticuerpos de union a hla-a2/wt1 | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| PE20241620A1 (es) | Anticuerpos terapeuticos que se unen al dominio serina proteasa de masp-2 y usos de estos | |
| PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| CO2024004055A2 (es) | Polipéptidos | |
| AR096445A1 (es) | Anticuerpos que se unen específicamente a la subunidad b de la toxina shiga | |
| EA202092122A1 (ru) | Антитела против tip-1 и их применения | |
| PE20212073A1 (es) | Modificacion de un anticuerpo para la union selectiva al tumor de cd47 |